BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 8594301)

  • 1. The specific binding of the platelet-activating factor (PAF) receptor antagonist WEB 2086 and the benzodiazepine flunitrazepam to rat hepatocytes.
    Svetlov SI; Barton JM; Olson MS
    Life Sci; 1996; 58(5):PL 81-6. PubMed ID: 8594301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
    Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
    Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of platelet-activating factor with rat hepatocytes: uptake, translocation, metabolism, and effects on PAF-acetylhydrolase secretion and protein tyrosine phosphorylation.
    Svetlov SI; Howard KM; Miwa M; Flickinger BD; Olson MS
    Arch Biochem Biophys; 1996 Mar; 327(1):113-22. PubMed ID: 8615681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
    Griffin K; Hong T; Levy JV
    Biochem Biophys Res Commun; 1989 Apr; 160(1):263-7. PubMed ID: 2540748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists.
    Domingo MT; Piro F; Broquet C; Auclair E; Chabrier PE; Braquet P
    Lipids; 1992 Aug; 27(8):582-6. PubMed ID: 1328798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC; Seldon PM; Barnes PJ; Giembycz MA
    Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of receptors for platelet-activating factor in guinea pig lung membranes.
    Gomez J; Bloom JW; Yamamura HI; Halonen M
    Am J Respir Cell Mol Biol; 1990 Sep; 3(3):259-64. PubMed ID: 2167700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of [3H]apafant binding to PAF receptor on rabbit platelet membranes: a comparison of a microplate filtration system and a standard method.
    Balsa D; Merlos M; Giral M; Ferrando R; García-Rafanell J; Forn J
    J Pharmacol Toxicol Methods; 1996 Sep; 36(1):53-62. PubMed ID: 8872920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial agonist effect of the platelet-activating factor receptor antagonists, WEB 2086 and WEB 2170, in the rat perfused heart.
    Hu W; McNicholl IK; Choy PC; Man RY
    Br J Pharmacol; 1993 Oct; 110(2):645-50. PubMed ID: 8242237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of pyrazolopyridines as modulators of [3H]flunitrazepam binding to the gaba/benzodiazepine receptor complex of the cerebellum.
    Supavilai P; Karobath M
    Eur J Pharmacol; 1981 Mar; 70(2):183-93. PubMed ID: 6114867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific [3H]Ro 5-4864 binding to rat spinal cord membranes: evidence for peripheral type benzodiazepine recognition sites.
    Villiger JW
    Neurosci Lett; 1984 May; 46(3):267-70. PubMed ID: 6330625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
    Tahraoui L; Floch A; Mondot S; Cavero I
    Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
    Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
    Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets.
    Robaut C; Durand G; James C; Lave D; Sedivy P; Floch A; Mondot S; Pacot D; Cavero I; Le Fur G
    Biochem Pharmacol; 1987 Oct; 36(19):3221-9. PubMed ID: 2822048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
    Floch A; Tahraoui L; Sedivy P; Cavero I
    J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of PAF receptors on human neutrophils using the specific antagonist, WEB 2086. Correlation between receptor binding and function.
    Dent G; Ukena D; Chanez P; Sybrecht G; Barnes P
    FEBS Lett; 1989 Feb; 244(2):365-8. PubMed ID: 2537761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes.
    Silva CL; Cruz HN; Violante FA; Cordeiro RS; Martins MA; Noël F
    Biochem Pharmacol; 1996 Jan; 51(2):193-6. PubMed ID: 8615889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species differences in PAF receptor binding in the lungs between hamster and guinea pig.
    Chen J; Giris N
    J Lipid Mediat Cell Signal; 1997 Jun; 16(2):63-74. PubMed ID: 9172049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
    Tahraoui L; Floch A; Cavero I
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
    Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.